Day: January 15, 2021

Modifications Des Modalités de Participation à L’assemblée Générale Mixte du 10 Février 2021 – Tenue à Huis Clos

La société DERICHEBOURG (ci-après la « Société ») informe ses actionnaires qu’en raison de la crise sanitaire liée à l’épidémie de COVID-19 et des dernières mesures gouvernementales prises pour faire face à cette l’épidémie, et conformément à l’Ordonnance n° 2020-1497 du 2 décembre 2020 portant prorogation et modification de l’Ordonnance n° 2020-321 du 25 mars 2020 autorisant la tenue des assemblées générales hors la présence des actionnaires et des personnes pouvant y assister, la Société a décidé de modifier les modalités de participation à son Assemblée Générale Mixte du 10 février 2021, initialement convoquée au 51 Chemin des Mèches – 94000 CRETEIL, en vue d’une tenue exceptionnelle à huis clos hors la présence physique des actionnaires, à son siège social, 119 avenue du Général Michel Bizot – 75012 Paris.Ainsi,...

Continue reading

Chvaletice Manganprojekt geht in nächste Phase des Genehmigungsverfahrens über

Projekt erreicht mit dem Abschluss des Vorprüfungsverfahrens wichtigen regulatorischen MeilensteinHighlights:Das tschechische Umweltministerium hat sein Vorprüfungsverfahren für die vorläufige Umweltverträglichkeitsprüfung (UVP) des Chvaletice Manganprojekts abgeschlossen.Euro Manganese kann nun zu den nächsten Phasen des Genehmigungsverfahrens übergehen. Das öffentliche und behördliche Feedback aus dem Vorprüfungsverfahren wird in die abschließende Umweltverträglichkeitsprüfung einfließen, die im Dezember 2021 abgeschlossen werden soll.Eine definitive Machbarkeitsstudie für das Projekt ist bereits in Arbeit und soll ebenfalls bis Ende des Jahres abgeschlossen werden.Die Beschaffung und Fertigung der Demonstrationsanlage des Projekts verläuft nach Plan, und die Lieferung an den Standort Chvaletice wird im Sommer 2021 erwartet.VANCOUVER,...

Continue reading

FAR Resources Ltd. Announces Stock Option Grant

VANCOUVER, British Columbia, Jan. 15, 2021 (GLOBE NEWSWIRE) — FAR Resources Ltd (“Far” of the “Company”) (CSE: FAT) announces that it has granted incentive stock options to consultants of the Company to purchase an aggregate of 4,800,000 common shares of the Company at an exercise price of $0.145 per common share expiring five years from the date of grant. The stock options are granted in accordance with the Company’s Stock Option Plan, which was approved by the shareholders at the Company’s annual general meeting on December 19, 2018, and the policies of the Canadian Securities Exchange.For and on behalf of the BoardJohn GammackPresident and CEOInformation ContactJohn Gammack, President & CEOFAR Resources, LTD.info@farresources.comThe Canadian Securities Exchange has neither approved nor disapproved the contents of this news...

Continue reading

Works Council consultation procedures have been finalized in relation to Columbus’ divestment of To-Increase

On 21 December 2020 (company release no. 19/2020) Columbus A/S announced that the Company had entered into an agreement to divest its software subsidiary To-Increase to Gilde Buy Out Partners and the management of To-Increase. The transaction was subject to Works Council consultation procedures being finalized in accordance with Dutch law. Works Council consultation procedures have now been finalized, and subsequently final Share Purchase Agreement (SPA) on the terms as described in company release no. 19/2020 has today been signed by Columbus A/S and Gilde Buy Out Partners. The transaction is expected to be fully completed during January 2021. The proceeds will be paid in cash upon closing of the transaction.  Ib Kunøe                                                                         Hans Henrik ThraneChairman of the Board                                                   ...

Continue reading

Can-Am Off-Road Maverick X3 Wins the Dakar Rally for an Unprecedented Fourth Consecutive Year Amidst More Competition

VALCOURT, Quebec, Jan. 15, 2021 (GLOBE NEWSWIRE) — Four. Wins. In a row. BRP (TSX: DOO; NASDAQ: DOOO) and its Can-Am Off-Road vehicles just scored their fourth consecutive Dakar Rally victory (2018–2021), sweeping the top 11 places. Together, Maverick X3 racers completed more than 114,024 miles (183,504 km) of extreme off-road racing during this years’ rally, achieving another historic performance.Crossing the line first in the combined Lightweight Vehicle category as well as the Side-by-Side class, Francisco López (Chile) and Juan Pablo Latrach Vinagre (Chile) led home a train of Maverick X3 racers. With a completely new route, the 2021 Dakar Rally, held in Saudi Arabia, created several dramatic moments and constant challenges for everyone—even the eventual race winners.“This is a dream come true and the feeling of winning the...

Continue reading

Le véhicule hors route Can-Am Maverick X3 remporte le Rallye Dakar pour la quatrième année consécutive malgré une compétition accrue!

VALCOURT, Québec, 15 janv. 2021 (GLOBE NEWSWIRE) — Quatre. Victoires. D’affilée. BRP (TSX: DOO; NASDAQ: DOOO) et ses véhicules Can-Am hors route viennent de rafler pour la quatrième année consécutive la tête du classement au Rallye Dakar (2018-2021), remportant les 11 premières positions. Ensemble, les pilotes de Maverick X3 ont effectué un parcours éprouvant de plus de 114 024 miles (183 504 km) hors route lors de la course de cette année, réalisant une nouvelle performance historique.Franchissant premier la ligne d’arrivée dans la catégorie des véhicules légers combinés ainsi que dans la catégorie côte à côte, Francisco López (Chili) et Juan Pablo Latrach Vinagre (Chili) ont mené le train des pilotes de Maverick X3. Avec un parcours entièrement revu, le Rallye Dakar 2021, qui s’est déroulé en Arabie saoudite, a créé plusieurs...

Continue reading

Genmab Announces that Janssen has been Granted U.S. FDA Approval for DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis

Company AnnouncementDARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) approved by U.S. FDA as the first and only therapy for newly diagnosed Light-chain (AL) amyloidosisAccelerated approval of DARZALEX FASPRO-based combination regimen supported by the Phase 3 ANDROMEDA (AMY3001) studyGenmab to receive USD 30 million milestone payment on first commercial saleCopenhagen, Denmark; January 15, 2021 – Genmab A/S (Nasdaq: GMAB) announced today that the U.S. Food and Drug Administration (U.S. FDA) has approved the use of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj), a subcutaneous formulation of daratumumab, in combination with bortezomib, cyclophosphamide, and dexamethasone (VCd) for the treatment of adult patients with newly diagnosed light-chain (AL) amyloidosis. A supplemental Biologics License Application (sBLA) for this indication...

Continue reading

Grace Responds to Revised Unsolicited Proposal from 40 North

COLUMBIA, Md., Jan. 15, 2021 (GLOBE NEWSWIRE) — W. R. Grace & Co. (NYSE: GRA) today announced that it has sent a letter to 40 North Management LLC (“40 North”) in response to 40 North’s January 11, 2021 revised unsolicited proposal to acquire Grace for $65 per share in cash.Following is the full text of the letter that was sent on January 15, 2021:January 15, 2021David Winter and David Millstone40 North Management LLC9 West 57th Street, 47th Fl.New York, NY 10019David and David –I am writing on behalf of the Grace Board of Directors in response to your letter and revised proposal of January 11, 2021.Our Board of Directors has met and discussed your revised proposal. We are willing to discuss a sale of Grace to 40 North in the context of our ongoing review of strategic alternatives. Any transaction would need to be at a price...

Continue reading

Emerald Bioscience to Change Name and Trading Symbol Effective Tuesday, January 19th

San Diego, Calif, Jan. 15, 2021 (GLOBE NEWSWIRE) — Emerald Bioscience, Inc. (OTCQB: EMBI) (“EMBI” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, has changed its name from Emerald Bioscience, Inc. to Skye Bioscience, Inc. The Company will trade under its new ticker symbol, “SKYE,” on the OTC effective at market open on Tuesday, January 19, 2021.About Emerald Bioscience, Inc.  Emerald Bioscience Inc. is a biopharmaceutical company developing differentiated, proprietary cannabinoid-derived molecules to treat diseases with significant unmet needs. The Company’s lead molecule, in preclinical studies, has demonstrated potential as a new class of therapy to lower intraocular pressure in patients with...

Continue reading

DIVERGENT Energy Services Announces Conditional Approval of its Debenture Restructuring Initiatives and Anticipated First Day of Trading

CALGARY, Alberta, Jan. 15, 2021 (GLOBE NEWSWIRE) — DIVERGENT Energy Services Corp. (DVG: TSX-V) (“Divergent”, the “Company“, or “DVG”) is pleased to announce that following the previously announced shareholder approval at its special meeting of shareholders on December 28, 2020 for the consolidation of its issued and outstanding common shares (the “Shares”) on the basis of ten (10) pre-consolidation Shares for one (1) post-consolidation Share (the “Consolidation”), it has received conditional approval from the TSX Venture Exchange (the “TSX-V”) for the Consolidation and will file articles of amendment implementing the Consolidation.The Shares will continue to be listed on the TSX-V under the symbol “DVG”, and the Shares are expected to begin trading on a post-Consolidation basis on the TSX-V on or about January 19, 2021....

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.